Article
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
Heart (British Cardiac Society) - 1 Aug 2011
Bouman Heleen J, Harmsze Ankie M, van Werkum Jochem W, Breet Nicoline J, Bergmeijer Th O, Ten Cate Hugo, Hackeng Christian M, Deneer Vera H M, Ten Berg Jurriën M
Abstract excerpt
BACKGROUND: An inadequate response to clopidogrel is mainly attributable to the variable formation of its active metabolite. The CYP2C19*2 loss-of-function polymorphism leads to reduced generation of the active metabolite and is, similarly to high on-treatment platelet reactivity (HPR), associated with recurrent atherothrombotic events following coronary stent implantation. AIM: To determine the relative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.